Display options
Cite
Mancano MA. Ticagrelor-induced pneumonitis and subsequent pulmonary hemorrhage; drug rash with eosinophilia due to boceprevir; hepatitis C reactivation after starting infliximab; hydralazine-associated immune glomerulonephritis; fluoroquinolones and retinal detachment. Hosp Pharm. 2014;49(6):498-501doi: 10.1310/hpj4906-498.
Mancano, M. A. (2014). Ticagrelor-induced pneumonitis and subsequent pulmonary hemorrhage; drug rash with eosinophilia due to boceprevir; hepatitis C reactivation after starting infliximab; hydralazine-associated immune glomerulonephritis; fluoroquinolones and retinal detachment. Hospital pharmacy, 49(6), 498-501. https://doi.org/10.1310/hpj4906-498
Mancano, Michael A. "Ticagrelor-induced pneumonitis and subsequent pulmonary hemorrhage; drug rash with eosinophilia due to boceprevir; hepatitis C reactivation after starting infliximab; hydralazine-associated immune glomerulonephritis; fluoroquinolones and retinal detachment." Hospital pharmacy vol. 49,6 (2014): 498-501. doi: https://doi.org/10.1310/hpj4906-498
Mancano MA. Ticagrelor-induced pneumonitis and subsequent pulmonary hemorrhage; drug rash with eosinophilia due to boceprevir; hepatitis C reactivation after starting infliximab; hydralazine-associated immune glomerulonephritis; fluoroquinolones and retinal detachment. Hosp Pharm. 2014 Jun;49(6):498-501. doi: 10.1310/hpj4906-498. PMID: 24958965; PMCID: PMC4062727.
Copy Download .nbib Format: NLM
Share it on

Hosp Pharm. 2014 Jun;49(6):498-501. doi: 10.1310/hpj4906-498.

Ticagrelor-induced pneumonitis and subsequent pulmonary hemorrhage; drug rash with eosinophilia due to boceprevir; hepatitis C reactivation after starting infliximab; hydralazine-associated immune glomerulonephritis; fluoroquinolones and retinal detachment.

Hospital pharmacy

Michael A Mancano

Affiliations

  1. Chair and Clinical Professor, Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, Pennsylvania; Clinical Advisor, Institute for Safe Medication Practices , Horsham, Pennsylvania.

PMID: 24958965 PMCID: PMC4062727 DOI: 10.1310/hpj4906-498

Abstract

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: [email protected]). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.

References

  1. Chest. 2014 Mar 1;145(3):639-641 - PubMed
  2. J Clin Gastroenterol. 2014 Feb;48(2):189-90 - PubMed
  3. JAMA. 2012 Apr 4;307(13):1414-9 - PubMed
  4. Clin Infect Dis. 2014 Jan;58(2):197-203 - PubMed
  5. J Clin Rheumatol. 2014 Mar;20(2):99-102 - PubMed
  6. J Hepatol. 2014 Apr;60(4):891-3 - PubMed

Publication Types